Table 1.
Clinical characteristics of the stomach adenocarcinoma patients included in this study.
| Characteristics | TCGA-STAD (n = 269) | GSE84426 (n = 76) |
|---|---|---|
| Age | ||
| ≤65 | 118 (43.87%) | 22 (28.95%) |
| >65 | 151 (56.13%) | 54 (71.05%) |
| Gender | ||
| Male | 166 (61.71%) | 54 (71.05%) |
| Female | 103 (38.29%) | 22 (28.95%) |
| Grade | ||
| G1 | 5 (1.86%) | – |
| G2 | 93 (34.57%) | – |
| G3 | 171 (63.57%) | – |
| Stage | ||
| I | 37 (13.75%) | – |
| II | 87 (32.34%) | – |
| III | 118 (43.87%) | – |
| IV | 27 (10.04%) | – |
| T stage | ||
| T1 | 13 (4.83%) | 0 |
| T2 | 55 (20.45%) | 3 (3.95%) |
| T3 | 133 (49.44%) | 25 (32.90%) |
| T4 | 68 (25.28%) | 48 (63.15%) |
| M stage | ||
| M0 | 253 (94.05%) | – |
| M1 | 16 (5.95%) | – |
| N stage | ||
| N0 | 85 (31.6%) | 9 (11.84%) |
| N1 | 68 (25.28%) | 33 (43.42%) |
| N2 | 63 (23.42%) | 33 (43.42%) |
| N3 | 53 (19.7%) | 1 (1.32%) |
| FPI | ||
| ≤0 | 108 (40.15%) | – |
| >0 | 161 (59.85%) | – |
| TIDE score | ||
| <0 | 84 (31.23%) | – |
| >0 | 185 (68.77%) | – |
STAD, stomach adenocarcinoma; FPI, ferroptosis potential index; TIDE, tumor immune dysfunction and exclusion.